← All indications
Neovascularization, Pathologic
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
Subtype terms (3)
More specific conditions that are subtypes of Neovascularization, Pathologic in the MeSH hierarchy.
- Choroidal Neovascularization
30 drugs (18 approved, 12 experimental)
- Corneal Neovascularization
12 drugs (10 approved, 2 experimental)
- Retinal Neovascularization
7 drugs (3 approved, 4 experimental)
Drugs by status
Phase 4 trials (4)
Phase 3 trials (5)
Phase 2 trials (5)
Phase 1 trials (8)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (19)
- Genentech
- Pfizer
- Novartis
- Bayer
- University of London
- Hacettepe University
- Instituto de Olhos de Goiania
- Oklahoma State University
- University of Melbourne
- University of Nottingham
- Vista Klinik
- Tennessee Retina
- Kim's Eye Hospital, Seoul, South Korea
- Sun Yat-Sen University
- University of Poitiers
- Association GEGO
- Ghent University
- Serb SA
- University Clermont Auvergne
Organization Involved with Phase 3 Indications (21)
- Novelion Therapeutics
- Regeneron
- Alcon
- Chengdu Kanghong Biotech Co.,Ltd.
- ZonMw: The Netherlands Organisation for Health Research and Development
- Shahid Beheshti University of Medical Sciences
- Johns Hopkins University
- Oregon Health and Science University
- Singapore National Eye Centre
- Utrecht University
- University of Bern
- Asociación para Evitar la Ceguera en México
- Instituto Universitario de Oftalmobiología Aplicada
- University of Basel
- Government of Mexico
- University of Castilla-La Mancha
- National Autonomous University of Mexico
- J. W. Goethe University
- Fondo de Investigacion Sanitaria
- Eyetech Pharmaceuticals
- Centro Medico Issemym
Organization Involved with Phase 2 Indications (47)
- Sirna Therapeutics
- Roche
- Adverum Biotechnologies, Inc.
- Allergan
- Santen Inc.
- Dong-A Pharmaceutical
- Iconic Therapeutics, Inc.
- Mateon Therapeutics
- TargeGen
- Mid-Atlantic Retina Consultations, Inc.
- Quark Pharmaceuticals
- Steba Biotech S.A.
- National Eye Institute (NEI)
- University of Illinois
- Ajou University
- Bascom Palmer Eye Institute
- California Retina Consultants
- Chang Gung University
- Harvard University
- Elman Retina Group
- Manhattan Eye, Ear & Throat Hospital
- Ophthalmological Association Edelweiss
- Retinal Consultants Medical Group
- University of Rochester
- University of Bonn
- Chongqing Medical University
- Retina Associates of Kentucky
- Tel Aviv University
- University of Cincinnati
- University of Vienna
- +17 more
Organization Involved with Phase 1 Indications (18)
- AnewPharma
- Genzyme
- Cancer Targeted Technology
- Light Sciences Oncology
- Opthea Pty Ltd.
- Parexel
- Retina Research Institute, LLC
- Retina Research Foundation
- Ophthalmic Consultants of Boston
- University of Lausanne
- Vitreous -Retina- Macula Consultants of New York (VRMNY)
- University of California, San Francisco
- University of Utah
- American University of Beirut
- Government of China
- Washington University in St. Louis
- University of Campania Luigi Vanvitelli
- Chinese Academy of Medical Sciences
Organization Involved with Other Experimental Indications (14)
- Oraya Therapeutics, Inc.
- Vision Research Foundation
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- United States Army
- Maastricht University
- Barnes Retina Institute
- Eastern Virginia Medical School
- Kresge Eye Institute
- Medical College of Hampton Roads
- University of Palermo
- Wayne State University
- Yonsei University
- L. V. Prasad Eye Institute
- University of Geneva